Thermedical, a privately held medical technology developer headquartered in Weston, Massachusetts, announced on October 8, 2026, the appointment of nine independent clinical and research experts to oversee its pivotal investigation of the Saline Enhanced Radiofrequency (SERF) Ablation System with the Durablate Catheter for patients with recurrent ventricular tachycardia. The appointments establish independent safety monitoring, clinical event adjudication and arrhythmia assessment for an investigational technology designed to reach abnormal electrical circuits embedded deep within the heart muscle. The study is enrolling patients whose ventricular tachycardia continues despite antiarrhythmic medication and previous catheter ablation procedures, a population with limited remaining treatment options.
The oversight appointments follow Thermedical’s initiation of the pivotal study in December 2025 and earlier feasibility research that demonstrated encouraging immediate suppression of difficult-to-treat ventricular arrhythmias. In a previously published 32-patient study, investigators reported 97% acute elimination of targeted clinical ventricular tachycardia and an 89% reduction in implantable cardioverter defibrillator therapies during follow-up. However, serious procedural complications were also reported, making independent monitoring particularly important as the technology advances into a larger clinical investigation.
Thermedical also announced that David J. Callans, associate director of electrophysiology at the University of Pennsylvania Health System, was scheduled to present early pivotal-study findings at VT Symposium 2026 in Brooklyn on October 9. The October 8 announcement did not disclose numerical results from the ongoing trial, meaning its immediate significance lies in strengthening clinical oversight and confirming continued development rather than establishing new pivotal efficacy outcomes.
Why does Thermedical’s pivotal SERF ablation study require independent clinical oversight?
Ventricular tachycardia is a potentially life-threatening cardiac arrhythmia characterised by rapid electrical activity originating in the ventricles. Sustained episodes can interfere with effective blood circulation and may cause dizziness, loss of consciousness, haemodynamic collapse or cardiac arrest. Patients with structural heart disease and recurrent ventricular tachycardia can remain at considerable risk even after receiving antiarrhythmic medicines, implantable defibrillators and conventional catheter ablation.
Thermedical’s trial focuses on patients whose arrhythmias have persisted despite those interventions. These individuals often have scar-related electrical circuits embedded within damaged heart muscle, where standard surface-based ablation may be unable to eliminate the tissue sustaining the abnormal rhythm. Attempting to reach those circuits using more extensive thermal lesions introduces additional safety considerations because the surrounding myocardium may already be weakened.
The company has appointed a four-member independent data safety monitoring board chaired by Wendy S. Tzou, director of cardiac electrophysiology at the University of Colorado School of Medicine. The board also includes John M. Miller of Indiana University’s Krannert Cardiovascular Research Center, Henry Huang of the University of Chicago and biostatistician George Wells of the University of Ottawa Heart Institute. Their responsibilities include periodically reviewing adverse events, assessing the quality of safety information and recommending whether the study should continue, be modified or stopped.
A separate clinical events committee, chaired by John Sapp Jr. of Dalhousie University, will adjudicate reported clinical safety events. Its additional members are Jaimie Manlucu of Western University and Jeanne Poole of the University of Washington. Independent adjudication is relevant because serious complications in patients with advanced structural heart disease may arise from the procedure, the underlying condition or other clinical circumstances, making consistent assessment essential.
How will the arrhythmia core laboratory evaluate ventricular tachycardia outcomes?
The third oversight component is an independent arrhythmia core laboratory responsible for reviewing and adjudicating tachyarrhythmia events throughout the investigation. John Sapp Jr. also chairs this group, alongside Alfred E. Buxton and Andre d’Avila, both associated with Harvard Medical School and Beth Israel Deaconess Medical Center. Their role is distinct from monitoring procedural safety because clinical effectiveness depends on whether targeted ventricular arrhythmias remain controlled after treatment.
Arrhythmia adjudication is especially important when patients already have implantable cardioverter defibrillators. These devices record rhythm disturbances and deliver antitachycardia pacing or electrical shocks when programmed treatment thresholds are reached. Device records can provide objective information about recurrent ventricular tachycardia, although interpretation must account for arrhythmia classifications, programming settings and changes in medical treatment.
The pivotal study’s registered efficacy measures include the proportion of targeted clinical ventricular tachycardias that cannot be induced at the end of the procedure and the proportion of patients free from recurrent monomorphic ventricular tachycardia at six months. These assess different dimensions of treatment performance. Immediate noninducibility indicates that investigators could not reproduce the targeted rhythm under the tested procedural conditions, while six-month freedom from recurrence provides evidence about the persistence of treatment benefit.
Independent review helps reduce variability in how investigators classify outcomes across participating institutions. It is particularly valuable in an open-label trial where physicians know which device is being used and there is no randomised control group. However, independent adjudication cannot remove every limitation associated with a single-arm study, especially when determining how outcomes compare with those that might have occurred under another treatment strategy.
How does SERF ablation reach ventricular tachycardia circuits beyond conventional catheter technology?
Conventional radiofrequency catheter ablation generally creates thermal lesions by delivering energy from an electrode positioned against the heart’s inner or outer surface. The objective is to destroy or electrically isolate tissue responsible for sustaining abnormal cardiac rhythms. However, lesion depth can be limited by tissue characteristics, energy delivery and safety constraints, creating difficulties when the arrhythmogenic circuit lies deep within the ventricular wall.
Thermedical’s SERF technology approaches this problem by combining radiofrequency energy with heated saline delivered through a needle-based catheter. The Durablate Catheter is engineered to introduce energy into myocardial tissue rather than relying exclusively on heat conducted from the surface. The saline acts as a mechanism for distributing thermal energy within the targeted region, potentially enabling larger or deeper lesions.
The company describes the system as offering control over lesion dimensions according to the clinical requirements of the procedure. This could allow electrophysiologists to target intramural arrhythmia substrates that are difficult to treat using standard techniques. Nevertheless, the ability to create deeper thermal lesions also increases the importance of controlling energy delivery and protecting surrounding structures.
For patients with scar-related ventricular tachycardia, lesion depth may be particularly relevant because electrical circuits can extend through complex three-dimensional regions of damaged myocardium. Successfully modifying those circuits may require more than treating the accessible endocardial surface. SERF is intended to provide another method of reaching such targets, but its procedural benefits and associated risks must be established through clinical evidence.
The technology should not be confused with pulsed field ablation, which uses electrical pulses to cause irreversible electroporation rather than primarily relying on thermal injury. Thermedical has separately investigated combining pulsed field ablation with SERF in feasibility research, but the current pivotal investigation evaluates the SERF system with the Durablate Catheter. Findings from the combined approach cannot automatically be attributed to the standalone pivotal procedure.
What did Thermedical’s earlier 32-patient SERF feasibility trial establish?
The earlier first-in-human feasibility investigation provides the most substantive published clinical evidence supporting the current programme. Results published in Circulation: Arrhythmia and Electrophysiology in 2022 described 32 patients treated at six centres for recurrent drug-refractory monomorphic ventricular tachycardia. All participants had implantable cardioverter defibrillators and had previously undergone conventional catheter ablation.
The patient population had substantial underlying cardiac disease. The mean age was 66 years, mean left ventricular ejection fraction was approximately 35%, and 56% had ischaemic cardiomyopathy. Participants had experienced a median of 45 device-delivered therapies, including shocks and antitachycardia pacing, during the three to six months before SERF treatment.
Investigators reported acute procedural success in 97% of patients, measured by the inability to induce the targeted clinical ventricular tachycardia at the conclusion of ablation. At an average follow-up of approximately five months, implantable defibrillator therapies were reduced by 89%. These findings suggested that the approach could suppress arrhythmia activity in patients who had already experienced treatment failure.
However, the reduction in defibrillator therapies is not equivalent to demonstrating an 89% reduction in mortality, an 89% probability of remaining arrhythmia-free or permanent elimination of ventricular tachycardia. Device therapies are influenced by arrhythmia frequency and programming, while the study had no concurrent randomised comparator. The small population and relatively short follow-up also limited the precision of conclusions about durability.
The findings nevertheless provided a scientific rationale for a larger investigation. The technology demonstrated the ability to create intramural lesions and achieve immediate control of difficult ventricular arrhythmias under study conditions. The pivotal trial must now establish whether that response can be reproduced more consistently and maintained over time.
Why do safety events in the earlier SERF study remain important for the pivotal trial?
The feasibility study also identified serious procedural complications that require careful consideration. Investigators reported two periprocedural deaths, one associated with embolic mesenteric infarction and the other with cardiogenic shock following extensive ablation. Two patients experienced mild strokes, while another developed a pericardial effusion requiring drainage.
These events occurred in a population with severe underlying cardiac disease, previous treatment failure and limited therapeutic options. The circumstances complicate interpretation of causality because patients undergoing ventricular tachycardia ablation may already face substantial procedural and cardiovascular risks. Nevertheless, the complications are clinically consequential and cannot be omitted from an assessment of the technology’s development.
The published investigators reported that serious adverse events considered probably or definitely related to the device occurred in approximately 6% of patients. They also observed that most serious events considered possibly related to the device occurred during the earlier procedures in the programme. The pattern may suggest a role for operator experience or procedural refinement, but the sample was too small to establish a reliable learning-curve effect.
The pivotal trial’s independent safety oversight therefore has an important role beyond procedural formality. It provides a structured mechanism for identifying complications, reviewing their possible relationship to the device and determining whether modifications are warranted. A larger dataset will be necessary to establish the frequency and severity of adverse outcomes more precisely.
The primary safety assessment will be particularly relevant when evaluating whether the potential benefit of reaching deeper arrhythmia circuits justifies additional procedural exposure. A device intended for patients with limited treatment alternatives may address a substantial unmet need, but that circumstance does not eliminate the requirement for an acceptable benefit-risk profile.
What does the pivotal SERF-VT study need to demonstrate before potential FDA approval?
The ongoing SERF-VT Ablation Study is registered under NCT05337241 and uses a staged, non-randomised, open-label, single-group design. It is evaluating the Thermedical Ablation System with the Durablate Catheter in adults with recurrent sustained monomorphic ventricular tachycardia associated with structural heart disease. Participants must have experienced relevant treatment failure and meet additional eligibility requirements concerning their cardiac condition and prior therapies.
The study includes assessments shortly after treatment and follow-up extending through six months. Its principal efficacy evaluations address immediate suppression of targeted ventricular tachycardia and freedom from recurrent monomorphic episodes during follow-up. These outcomes are designed to provide evidence about both procedural effectiveness and durability.
Patient selection is particularly important. The registered criteria require substantial documented arrhythmia activity and previous use of appropriate treatments, while excluding certain patients with severe cardiac or other medical conditions. Consequently, any eventual findings would be most directly applicable to the refractory population studied rather than to all patients with ventricular tachycardia.
The United States Food and Drug Administration previously permitted the clinical investigation under the applicable investigational device framework. Thermedical has also described the system as having received Breakthrough Device designation. Neither development constitutes marketing approval, and the device remains investigational for ventricular tachycardia treatment.
Thermedical intends to use the pivotal investigation to support a potential FDA Premarket Approval submission. That pathway requires regulatory evaluation of device safety and effectiveness, including whether the clinical evidence supports its intended use. Submission timing and any eventual marketing decision will depend on the study’s completion, the quality of the supporting evidence and regulatory review.
Could deeper ventricular ablation create a new treatment option for patients with recurrent ICD shocks?
Repeated implantable cardioverter defibrillator shocks represent an important clinical burden in patients with refractory ventricular tachycardia. Although defibrillators can terminate dangerous arrhythmias and reduce the risk of sudden arrhythmic death in appropriate patients, they do not necessarily eliminate the electrical circuits causing repeated episodes. Patients may therefore continue experiencing shocks and hospitalisations despite having functioning devices.
Successful catheter ablation can reduce arrhythmia burden, but recurrence remains a problem, particularly among patients with extensive ventricular scarring or intramural substrates. Thermedical’s proposed clinical advantage lies in addressing circuits that conventional energy delivery cannot adequately reach. If the approach produces sustained arrhythmia suppression, it could become a treatment option for selected patients after previous procedures have failed.
The potential benefit would need to be evaluated alongside outcomes that matter to patients and healthcare providers. These include recurrent ventricular tachycardia, ICD shocks, hospitalisations, repeat procedures and procedural complications. Demonstrating immediate noninducibility alone would not establish improvement across all these measures.
From a healthcare delivery perspective, the system would also require specialised electrophysiology expertise and integration with existing mapping and catheterisation equipment. Advanced ventricular tachycardia ablation is generally concentrated in experienced cardiac centres because procedures can involve complex anatomy and unstable patients. Any future commercial deployment would therefore depend on operator training, institutional capability and appropriately defined patient selection.
Thermedical remains privately held, and the company has not disclosed a commercial launch forecast or revenue projection for SERF. Its development has received support from venture financing and public research programmes, including a $3 million National Heart, Lung, and Blood Institute grant supporting the pivotal investigation. The funding helps advance clinical evaluation but should not be interpreted as evidence of regulatory approval or future commercial success.
What will determine whether Thermedical’s SERF technology advances into clinical practice?
The most important next milestone will be the availability of adjudicated pivotal-study results showing whether the procedural benefits observed in the earlier feasibility population can be reproduced. Six-month recurrence findings will be particularly important because early suppression of ventricular tachycardia may not translate into sustained control. Complete reporting of implantable defibrillator therapies, repeat interventions and adverse events will provide additional context for the clinical benefit-risk assessment.
The early findings scheduled for presentation by David J. Callans at VT Symposium 2026 may offer an initial indication of progress, but the October 8 company announcement did not disclose the relevant numerical dataset. Preliminary observations from an ongoing trial should also be distinguished from final results incorporating the intended follow-up period and independent adjudication. Any early efficacy signal will require confirmation from the broader study population.
Safety will remain a decisive consideration because the technology deliberately delivers thermal energy within myocardial tissue to reach difficult arrhythmia substrates. The previous feasibility programme established that serious complications can occur in this high-risk treatment setting, while also demonstrating promising acute control of targeted arrhythmias. The pivotal investigation must provide more precise estimates of both outcomes.
The independent monitoring structure announced by Thermedical strengthens the clinical governance of a study addressing a substantial unmet treatment need. It brings together specialists responsible for reviewing safety, adjudicating clinical events and determining whether arrhythmia suppression persists beyond the procedure itself. The ultimate significance of SERF will depend not on the appointments alone, but on whether the resulting clinical evidence establishes that deeper myocardial ablation offers durable ventricular tachycardia control with risks acceptable for the refractory patients it is intended to treat.
